The fund’s investment objective is to provide capital growth through investment in European and other companies. The emphasis of the fund will be investment in European companies. The fund may also invest in companies headquartered or quoted outside Europe where those companies have material or critical operations within or derive significant business from Europe. Fixed interest securities may be included in the portfolio. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Name | % Net Assets |
---|---|
UBS | 4.5% |
Novartis | 4.4% |
BNP Paribas | 4.4% |
DnB NOR Bank | 4.0% |
Roche Holding | 3.8% |
Brenntag | 3.5% |
Hexagon | 3.5% |
Assa Abloy | 3.4% |
Svenska Cellulosa | 3.3% |
Henkel | 3.3% |
Key | % Net Assets |
---|---|
UBS | 4.5% |
Novartis | 4.4% |
BNP Paribas | 4.4% |
DnB NOR Bank | 4.0% |
Other | 82.7% |
Date | 21-Nov-2024 |
---|---|
NAV | 181.70p |
Currency | GBP |
Change | -0.30p |
% | -0.16% |
YTD change | -12.10p |
YTD % | -6.24% |
Fund Inception | 03/10/2003 |
---|---|
Fund Manager | Leon Howard-Spink |
TER | 1.68 (15-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.15 |
You are here: research